Matchpoint Therapeutics has closed a $150 million Series B financing, money the private Watertown, Massachusetts biotech says is meant mainly to carry its lead drug candidate into human testing for the first time. The round, announced 7 October 2026, was co-led by Nextech Invest and Norwest, with Invus, BB Biotech, T1D Fund and BOLD Longevity Growth joining as new investors alongside returning backers Access Biotechnology, Atlas Venture, Sanofi Ventures and Digitalis Ventures.
Matchpoint's raise, in four figures
Figures from Matchpoint's 7 October 2026 Series B announcement and its July 2025 Novartis agreement announcement.
Watertown, by way of Stanford and Harvard
Matchpoint Therapeutics emerged from stealth in October 2022, built by researchers from Stanford University and Harvard Medical School around what the company calls its Advanced Covalent Exploration platform — a chemistry approach meant to form selective, irreversible bonds with disease-relevant proteins, aiming for drugs with improved potency, greater selectivity and lower systemic exposure than conventional small molecules. A $70 million Series A led by Sanofi Ventures followed in 2022, on top of an earlier $30 million seed round.
“This Series B financing reflects our substantial progress in the discovery of differentiated first-in-class oral therapies for autoimmune and inflammatory diseases.” Andre Turenne, Chief Executive Officer, Matchpoint Therapeutics — 7 October 2026 announcement
A molecule Novartis already optioned once
Matchpoint's covalent-chemistry approach had already drawn pharma interest before this round: in July 2025, Novartis signed an exclusive option and license agreement with Matchpoint covering oral inhibitors for multiple inflammatory diseases, a deal reported at up to $1 billion in potential total payments including upfront cash and research funding. That program continues on its own track. The Series B instead funds MPT-062, which Matchpoint has kept outside the Novartis deal and fully in its own hands as its lead, wholly owned asset.
Three things the raise buys
A first human trial
MPT-062 has no human efficacy or safety data yet; Matchpoint says clinical development begins in 2027, which this financing is sized to fund through proof-of-concept.
A platform Novartis already vetted
Matchpoint's Advanced Covalent Exploration platform underpins both MPT-062 and the separate Novartis-optioned program, giving the company two pharma-grade validations of the same underlying chemistry.
New board seats for new money
Nextech Invest's Kanishka Pothula and Norwest's Brian Matesic join Matchpoint's board as part of the round, the kind of governance change that typically accompanies a company's transition toward clinical-stage spending.
A crowded shelf of autoimmune pills
Oral small-molecule treatments for autoimmune and inflammatory disease already include JAK inhibitors such as AbbVie's Rinvoq and Pfizer's Cibinqo, alongside a newer wave of allosteric and covalent TYK2 inhibitors from companies including Nimbus Therapeutics and Sudo Biosciences. Matchpoint's pitch is mechanistic rather than positional: a covalent T-cell modulator, MPT-062's developers argue, can achieve more selective, longer-lasting target engagement than a reversible small molecule, without resorting to an injected biologic. None of that is yet tested in a patient.
The shelf MPT-062 is aiming for
$132.75B → $254.6B
Global autoimmune disease therapeutics market, 2025 to 2034, as forecast by DelveInsight; a separate Mordor-style estimate puts the narrower 2025-to-2030 window at $231.15B to $336.26B, underlining how widely autoimmune-market estimates diverge by scope and methodology.
Sources: DelveInsight, Autoimmune Disease Therapeutics — Market Insights, Competitive Landscape, and Market Forecast report · Market research estimate cited via GII/ResearchAndMarkets listing, Autoimmune Disease Therapeutics Market
Regulatory News outlook
Biologics held roughly two-thirds of this market in 2025 by DelveInsight's own accounting, so MPT-062's addressable slice — oral small-molecule, mechanism-differentiated therapy — is a fraction of either headline figure above, not the whole of it. A Novartis-grade pharma partner optioning a related covalent program is the clearer signal of commercial interest than the category total.
How we got here: We note DelveInsight's stated ~66% 2025 biologics share of the market to flag that MPT-062's oral small-molecule category is meaningfully smaller than either outlook's headline figure, without computing our own dollar estimate for that narrower slice, since neither publisher breaks out a covalent-chemistry or T-cell-modulator sub-segment.
MPT-062 against other oral autoimmune mechanisms
| Product | Mechanism | Route | Stage |
|---|---|---|---|
| MPT-062 (Matchpoint Therapeutics) | Covalent, irreversible T-cell modulator | Oral | Preclinical; clinic expected 2027 |
| Rinvoq / upadacitinib (AbbVie) | Reversible JAK1 inhibitor | Oral | FDA approved, multiple indications |
| Cibinqo / abrocitinib (Pfizer) | Reversible JAK1 inhibitor | Oral | FDA approved, atopic dermatitis |
| TYK2 programs (Nimbus Therapeutics, Sudo Biosciences) | Allosteric/covalent TYK2 inhibition | Oral | Clinical-stage |
From each company's own labelling and public disclosures; not a clinical comparison. MPT-062 has not yet entered human trials.
From a 2022 stealth launch to a third raise
Matchpoint's path to a $150 million Series B
- 2021
Seed financing
Matchpoint raises a $30 million seed round to build its covalent-chemistry drug-discovery platform.
- October 2022
Emerges from stealth
Matchpoint launches publicly, founded by researchers from Stanford University and Harvard Medical School, alongside a $70 million Series A led by Sanofi Ventures.
- July 2025
Novartis option and license deal
Novartis signs an exclusive option and license agreement for oral inhibitors across multiple inflammatory diseases, worth up to $1 billion in potential payments.
- 7 October 2026
$150 million Series B closes
Co-led by Nextech Invest and Norwest, with four new institutional investors joining, to fund MPT-062 toward clinical proof-of-concept.
- 2027
Clinical development expected to begin
Matchpoint has said it expects to dose its first patients with MPT-062, moving the company into clinical-stage spending for the first time.
What this raise still leaves unanswered
Matchpoint has not disclosed MPT-062's specific molecular target, its planned first indication, or the design of the trial that will take it into the clinic in 2027 — all facts that would let an outside reader judge the molecule's chances rather than the platform's pedigree. The company's own disclosures also do not break out how much of the $150 million is earmarked for MPT-062 specifically versus its broader covalent-chemistry pipeline, including the Novartis-funded program that continues in parallel.
- Financing: $150 million Series B closed 7 October 2026, co-led by Nextech Invest and Norwest, lifting total equity raised since 2021 to roughly $250 million.
- Use of proceeds: advancing MPT-062, an oral covalent T-cell modulator, to clinical proof-of-concept, with clinical development expected to begin in 2027.
- Separate program: a July 2025 Novartis option and license deal for oral inflammatory-disease inhibitors, worth up to $1 billion in potential payments, continues independently of the Series B.
- Not yet public: MPT-062's molecular target, planned first indication, and the design of its first human trial.
Sources & further reading
- BioSpace, “Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset,” 7 October 2026. biospace.com
- Fierce Biotech, “Matchpoint nets $150M series B to take covalent med into clinic,” October 2026. fiercebiotech.com
- pharmaphorum, “Matchpoint scores $150m for I&I drugs, and other financings,” October 2026. pharmaphorum.com
- BioSpace, “Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases,” July 2025. biospace.com
- DelveInsight, Autoimmune Disease Therapeutics market report. delveinsight.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What is Matchpoint's Series B for?
The $150 million round, closed 7 October 2026 and co-led by Nextech Invest and Norwest, is earmarked mainly to advance MPT-062, Matchpoint's oral covalent T-cell modulator, to clinical proof-of-concept; clinical development is expected to begin in 2027. Some funds also support the company's broader covalent-chemistry pipeline, including a program funded under its 2025 Novartis agreement.
Has MPT-062 been tested in people yet?
No. As of this financing, MPT-062 is preclinical, with no reported human efficacy or safety data. Matchpoint has said it expects to begin clinical development in 2027.
What is Matchpoint's deal with Novartis?
In July 2025, Matchpoint and Novartis announced an exclusive option and license agreement covering oral inhibitors for multiple inflammatory diseases, worth up to $1 billion in potential total payments, including upfront cash and research funding reported at up to $60 million. That program continues alongside, and separately from, the Series B-funded MPT-062 work.
Who invested in the Series B?
Nextech Invest and Norwest co-led the round. New investors Invus, BB Biotech, T1D Fund and BOLD Longevity Growth joined existing backers Access Biotechnology, Atlas Venture, Sanofi Ventures and Digitalis Ventures. Nextech's Kanishka Pothula and Norwest's Brian Matesic are joining Matchpoint's board.
